Freenome (NASDAQ:FRNM) Shares Climb 5.1% – Here’s What Happened

Shares of Freenome (NASDAQ:FRNM – Get Free Report) traded up 5.1% during mid-day trading on Thursday. The stock traded as high as $10.51 and last traded at $10.2290. 180,531 shares were traded during mid-day trading, a decline of 79% from the average session volume of 846,109 shares. The stock had previously closed at $9.73.

Wall Street Analyst Weigh In

Several analysts recently commented on FRNM shares. Jefferies Financial Group started coverage on Freenome in a report on Monday, August 17th. They set a “buy” rating and a $17.00 target price on the stock. BTIG Research reissued a “buy” rating on shares of Freenome in a report on Wednesday, November 11th. Guggenheim started coverage on Freenome in a research report on Thursday, August 20th. They issued a “buy” rating and a $21.00 price objective on the stock. TD Cowen started coverage on shares of Freenome in a research note on Tuesday, August 18th. They set a “buy” rating and a $17.00 price objective on the stock. Finally, Wall Street Zen raised shares of Freenome to a “sell” rating in a report on Saturday, September 26th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

View Our Latest Stock Analysis on FRNM

Freenome Stock Up 5.7%

The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of 20.16 and a beta of 0.60. The firm has a 50 day moving average price of $13.60.

Freenome (NASDAQ:FRNM – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported $1.10 earnings per share for the quarter. The business had revenue of $183.49 million during the quarter, compared to analyst estimates of $106.50 million.

Freenome Company Profile

(Get Free Report)

Freenome is a biotechnology company developing blood-based tests intended to detect cancer at earlier stages. Its approach combines analysis of biological signals—including DNA and other biomarkers—with computational tools to identify patterns associated with disease. The company’s research has focused on multiomics screening, particularly for colorectal cancer. Freenome has evaluated its blood-based colorectal cancer test in clinical studies; the test is investigational, and its availability and regulatory status may vary.

Featured Stories

Receive News & Ratings for Freenome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freenome and related companies with MarketBeat.com's FREE daily email newsletter.